Iron Absorption and Exercise

February 25, 2020 updated by: Stephen R. Hennigar, Ph.D., Florida State University

Fractional Iron Absorption in Response to an Acute Bout of Exercise

Iron is a nutritionally essential mineral required for optimal physical and cognitive performance. Endurance exercise often leads to declines in iron status; however, the reason for the decline is not known. The primary objective of the proposed study is to determine the effects of an acute bout of strenuous endurance exercise on iron absorption and status and markers of inflammation in human volunteers. The investigators hypothesize that an acute bout of strenuous endurance exercise, compared to rest, will reduce iron absorption, resulting in diminished iron status, and that reduced iron absorption will be negatively associated with markers of inflammation. A secondary objective is to monitor iron status throughout a season of competition.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Tallahassee, Florida, United States, 32306
        • Florida State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Members of the Florida State University Cross Country team
  • Refrain from using any pain-relievers (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs such as aspirin, Advil®, Aleve®, Naprosyn®), or any other aspirin-containing product on the 2 study days
  • Refrain from using vitamin or mineral supplements on the study days

Exclusion Criteria:

  • Musculoskeletal injury that compromise the ability to exercise

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Exercise
During the exercise arm, volunteers will complete a planned workout, as prescribed by the coach. The workout will be designed to be strenuous and induce an inflammatory response.
Participants will consume a meal containing a stable iron isotope following exercise or rest.
EXPERIMENTAL: Rest
The rest arm will be coordinated with a planned non-workout day, as prescribed by the coach, where volunteers are either scheduled to not run or go for an easy recovery run (<6 miles at a self-described "easy" pace) later in the afternoon.
Participants will consume a meal containing a stable iron isotope following exercise or rest.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in fractional iron absorption
Time Frame: Red blood cells collected on day 0 and day 14
Stable iron isotopes
Red blood cells collected on day 0 and day 14

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in concentration of ferritin in ng/mL
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14
Change in concentration of soluble transferrin receptor in nmol/L
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14
Change in concentration of hemoglobin in g/L
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14
Change in concentration of hematocrit as %
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14
Change in concentration of hepcidin in ng/mL
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14
Change in concentration of IL-6 in pg/mL
Time Frame: Day 0 and day 14
Blood measure
Day 0 and day 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 22, 2019

Primary Completion (ACTUAL)

December 4, 2019

Study Completion (ACTUAL)

December 4, 2019

Study Registration Dates

First Submitted

August 12, 2019

First Submitted That Met QC Criteria

September 4, 2019

First Posted (ACTUAL)

September 6, 2019

Study Record Updates

Last Update Posted (ACTUAL)

February 27, 2020

Last Update Submitted That Met QC Criteria

February 25, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron-deficiency

Clinical Trials on Meal

3
Subscribe